Cargando…
Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases
BACKGROUND: Fingolimod (FTY), an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS), has been associated with a significant rebound of disease activity after cessation of therapy. METHODS: We present the clinical and radiological findings of two patients with severe rebou...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503590/ https://www.ncbi.nlm.nih.gov/pubmed/31105771 http://dx.doi.org/10.1177/1756286419846818 |